BioSig Appoints Vice President of Engineering

BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, has appointed Dr. Barry Keenan, Ph.D., MBA, PMP to head up BioSig’s advanced product development.

Dr. Keenan brings to the company over 20 years of experience in R&D, product development and commercialization and deep industry expertise in a range of sectors, including neuromodulation, deep brain stimulation, sensing, imaging and cardiac pacing.

Biomedical engineer by training, Dr. Keenan spent over nine years at Medtronic Diabetes, where he was responsible for all algorithm development, and successfully developed the algorithms for the MiniMed Paradigm Veo, the first semi-closed loop system; and iPro2 Professional Continuous Glucose Monitoring (CGM), glucose monitoring algorithm. One of the highlights of Dr. Keenan’s career was development and successful clinical evaluation of the MiniMed 670G, the world’s first artificial pancreas. This invention became one of the top revenue-generating products for Medtronic and the research was featured in Time magazine’s 25 Best Inventions of 2013 and 2016 and named as one of the Best Medical Technologies of 2016.

“Barry’s second-to-none academic training and industry expertise are very hard to come by, and we are particularly impressed with his achievements in neuromodulation,” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies. “As we accelerate our research activities, we need strong engineering leadership and commercial expertise to grow our product development. We are confident that Barry will become an invaluable part of our team.”

Since 2014, Dr. Keenan has been actively involved with the Alfred Mann Foundation for Scientific Research as chief technology officer and vice president of Research & Development, and later as a board member of the Alfred Mann Institute for Biomedical Engineering. During Dr. Keenan’s engagement with the Foundation he managed an R&D department of over 40 scientists and engineers consisting of software, firmware, electrical, mechanical and ASIC groups developing innovative medical devices, implanted neuromodulation and sensing systems. 

Dr. Keenan is a winner of several awards, is a Medtronic Technical Fellow, and is being inducted into this year’s College of Fellows of the American Institute for Medical and Biological Engineering (AMIBE). His team at Medtronic won Technical Contributors of the Year for their work in the artificial pancreas, which also achieved ‘Best of What’s New’ in the health category by Popular Science. Dr. Keenan is an inventor of 39 patents and authored over 30 scientific manuscripts and book chapters.

“Having followed BioSig’s development over the years, I am excited about its future as a technology company with cutting-edge signal processing capabilities. I look forward to contributing my knowledge and exploring opportunities for wider applications of BioSig’s core technology,” commented Dr. Keenan.

The company previously appointed Sherpa Technology Group to architect IP strategy and announced a new advanced research agreement with Mayo Clinic in November 2018.

On Feb. 20, the company announced that it successfully conducted first patient cases using PURE EP System, its U.S. Food and Drug Administration (FDA)-approved proprietary signal acquisition and processing technology. Early results of the studies suggested improved cardiac signal detection and fidelity.

BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Led by a management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.

The PURE EP System is a cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP System in August 2018.